Sara Giunti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Giunti has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
G. Gruden
University of Turin
2 shared publications- Giovanni Camussi
Department of Medical Sciences, University of Torino, 10126 Torino, Italy
2 shared publications - Graziella Bruno
Department of Medical Sciences, University of Turin, Turin, Italy
2 shared publications Nish Chaturvedi
Department of Epidemiology and Public-Health, University College London, London, UK
2 shared publicationsS. Pinach
University of Turin
2 shared publicationsCristina Amione
Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy
1 shared publication
Latest Publications
- 20 June 2017
- Published by Springer Nature in Acta Diabetologica
- Vol. 54 (9) , 871-876
Incidence of prolonged QTc and severe hypoglycemia in type 1 diabetes: the EURODIAB Prospective Complications Study
- 20 June 2017
- Published by Springer Nature in Acta Diabetologica
- Vol. 54 (9) , 871-876
Incidence of prolonged QTc and severe hypoglycemia in type 1 diabetes: the EURODIAB Prospective Complications Study
- 30 October 2007
- Published by Springer Nature in Diabetologia
- Vol. 51 (1) , 198-207
Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells
Diabetic nephropathy is characterised by mesangial extracellular matrix accumulation. Monocyte chemoattractant protein-1 (MCP-1), a chemokine promoting monocyte infiltration, is upregulated in the diabetic glomerulus. We performed in vitro and in vivo studies to examine whether MCP-1 may have prosclerotic actions in the setting of diabetes, presumably via its receptor, chemokine (C-C motif) receptor 2 (CCR2), which has been described in mesangial cells.
- 30 October 2007
- Published by Springer Nature in Diabetologia
- Vol. 51 (1) , 198-207
Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells
Diabetic nephropathy is characterised by mesangial extracellular matrix accumulation. Monocyte chemoattractant protein-1 (MCP-1), a chemokine promoting monocyte infiltration, is upregulated in the diabetic glomerulus. We performed in vitro and in vivo studies to examine whether MCP-1 may have prosclerotic actions in the setting of diabetes, presumably via its receptor, chemokine (C-C motif) receptor 2 (CCR2), which has been described in mesangial cells.
- 1 March 2006
- Published by Elsevier in Kidney International
- Vol. 69 (5) , 856-863
The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells
- 1 March 2006
- Published by Elsevier in Kidney International
- Vol. 69 (5) , 856-863
The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells
- Open Access
- 1 September 2005
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (9) , 2255-2257
Electrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes
- 1 September 2005
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (9) , 2255-2257
Open AccessElectrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes